Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy-Reference-Cited by-同舟云学术

Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy

Published:2020-03 Issue: Volume:40 Page:100640
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Bachanova Veronika,Perales Miguel-Angel,Abramson Jeremy S.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference55 articles.

1. SEER cancer statistics review,1975

2. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity;Sehn;Blood,2015

3. Non-Hodgkin’s lymphoma;Freedman,2015

4. Non-Hodgkin lymphoma;Roschewski,2014

5. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma;Horn;Blood,2013

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective;Indian Journal of Cancer;2024-04

2. Programa de inoculación de estrés para el manejo del malestar emocional asociado a la terapia de células CAR-T: caso clínico;Psicooncología;2023-10-26

3. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma;Experimental Hematology & Oncology;2023-08-14

4. Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023;Human Vaccines & Immunotherapeutics;2023-08

5. CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes;Haematologica;2023-06-22